本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Atea Pharmaceuticals, Inc.

3.14
-0.1600-4.85%
盤後3.140.00000.00%16:57 EDT
成交量:18.21萬
成交額:57.40萬
市值:2.49億
市盈率:-1.95
高:3.29
開:3.29
低:3.10
收:3.30
52周最高:4.15
52周最低:2.46
股本:7,935.76萬
流通股本:6,000.97萬
量比:1.05
換手率:0.30%
股息:- -
股息率:- -
每股收益(TTM):-1.6118
每股收益(LYR):-1.9983
淨資產收益率:-32.38%
總資產收益率:-20.16%
市淨率:0.68
市盈率(LYR):-1.57

資料載入中...

2024/02/02

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/02/02

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/02/02

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/11/28

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/11/09

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/09

重要事件披露

Form 8-K - Current report
2023/10/02

超過5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/08/09

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/08/08

重要事件披露

Form 8-K - Current report
2023/06/22

重要事件披露

Form 8-K - Current report
2023/05/22

超過5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2023/05/08

重要事件披露

8-K - Current report
2023/05/08

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2023/02/28

重要事件披露

8-K - Current report
2023/02/28

年度報告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2023/02/10

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/10

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/09

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/11/07

重要事件披露

8-K - Current report
2022/11/07

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]